Opinion|Videos|October 18, 2023

Common Clinical Presentations of Metastatic Melanoma

Author(s)Hussein A. Tawbi, MD, PhD

Hussein Tawbi, MD, PhD, details the incidence rate of melanoma and that appropriate diagnosis includes an MRI to check for brain metastases and molecular testing for BRAF mutations.

Episodes in this series

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 1 Case Presentation: A 78-Year-Old Man With Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 2 Common Clinical Presentations of Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 3 Significance of Biomarker and Genetic Testing in Diagnosing Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 4 Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 5 The Role of Lymphocyte-Activation Gene 3 (LAG-3) in Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 6 Relatlimab/Nivolumab in Metastatic Melanoma: Data From the RELATIVITY-047 Trial

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 7 IO Monotherapy Versus Combination Dual IO Therapy for the First-Line Treatment of Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 8 Key Trial Data in the Frontline Treatment of Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 9 Managing Adverse Events in Patients With Metastatic Melanoma Receiving First-Line Systemic Therapy

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 10 Case Presentation: A 67-Year-Old Woman With Stage IV Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 11 Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma with a BRAF Mutation

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 12 Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib in Metastatic Melanoma: Data From the DREAMseq Trial

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 13 Second-Line Treatment Options for Patients With Metastatic or Unresectable Melanoma After Disease Progression

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 14 Clinical Pearls on the Treatment of Metastatic and Unresectable Melanoma

Related Content

Nearly Half of TIL Referrals in Melanoma Not Treated in Single-Center Study

February 9th 2026

Real-World Study Confirms Efficacy of Lifileucel in Advanced Melanoma

ByJonah Feldman

February 6th 2026

FDA Grants Orphan Drug Designation to IFx-2.0 for Advanced Melanoma

ByJonah Feldman

February 2nd 2026

Neoadjuvant Pembrolizumab Achieves High pCR Rates in Desmoplastic Melanoma

ByJonah Feldman

January 30th 2026

FDA Clears IND for Phase 3 Trial of iSCIB1+ in Advanced Melanoma

ByJonah Feldman

January 26th 2026

Latest CME

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Manmeet Ahluwalia, MD, MBA

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

Shaina Rozell, MD, MPH; Seth A. Wander, MD, PhD

The 2nd Annual Hawaii Breast: A Multidisciplinary Case-Based Conference

The 2nd Annual Hawaii Breast: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD; Benjamin Falit, MD; Jami Fukui, MD; Laura Huppert, MD; Sara A. Hurvitz, MD, FACP; Jodi Kagihara, MD; Irene Kang, MD; William Loui, MD, FACP; Ashley Marumoto, MD; Rebecca Shatsky, MD; Naoko Takebe, MD, PhD; Melinda Telli, MD, FASCO; Rachel Thelen, FNP-C, AOCNP; Teruo Yamauchi, MD, MS

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

43rd Annual Miami Breast Cancer Conference®

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Munaf Alkadimi, MD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO